Physician profile
Matthew C Lambert
NPI 1992840805
$9,259.77
in general payments reported to CMS, 2019-2025
37 companies · $2,014 in 2025
The $2,014 reported for 2025 was more than what 89% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,070 · 2020: $1,018 · 2021: $1,067 · 2022: $1,065 · 2023: $1,421 · 2024: $1,604 · 2025: $2,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,006 · Education: $32.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,006.45 |
| Education | $32.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $862.99 | 2019-2025 | Auryxia, Vafseo |
| Astrazeneca Pharmaceuticals LP | $799.74 | 2019-2025 | Lokelma, Farxiga |
| Novartis Pharmaceuticals Corporation | $688.22 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $608.36 | 2019-2025 | Jynarque |
| Travere Therapeutics, INC. | $524.42 | 2022-2025 | |
| Amgen INC. | $509.65 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Mallinckrodt Hospital Products INC. | $483.79 | 2020-2025 | Acthar, Terlivaz |
| Ani Pharmaceuticals, INC. | $473.33 | 2022-2025 | Purified Cortrophin Gel |
| Vifor Pharma, INC. | $446.19 | 2020-2025 | Veltassa |
| Calliditas Therapeutics US INC. | $443.73 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $411.79 | 2019-2024 | Benlysta, Jesduvroq |
| Bayer Healthcare Pharmaceuticals INC. | $357.51 | 2021-2025 | |
| Horizon Therapeutics Plc | $283.67 | 2019-2023 | Krystexxa |
| Mallinckrodt Enterprises LLC | $270.49 | 2019 | |
| Aurinia Pharma U.S., INC. | $262.41 | 2021-2025 | Lupkynis |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $247.58 | 2024-2025 | Rivfloza, Wegovy |
| Daiichi Sankyo INC. | $192.00 | 2019-2023 | Injectafer |
| Fresenius USA Marketing, INC. | $175.34 | 2019-2024 | Velphoro |
| Lilly USA, LLC | $138.08 | 2024-2025 | Jardiance |
| Ardelyx, INC. | $125.68 | 2024-2025 | Ibsrela |
| Recor Medical INC | $124.91 | 2025 | Paradise Ultrasound Renal Denervation System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.40 | 2023-2025 | Jardiance |
| Ultragenyx Pharmaceutical INC. | $98.80 | 2019-2022 | |
| Rockwell Medical, INC. | $87.59 | 2020 | |
| Kyowa Kirin, INC. | $76.47 | 2023-2025 | Crysvita |
| Baxter Healthcare | $64.77 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $56.53 | 2025 | Empaveli |
| Inari Medical, INC. | $56.11 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Ascendis Pharma Endocrinology INC | $49.30 | 2025 | Yorvipath |
| Alexion Pharmaceuticals, INC. | $48.76 | 2019-2025 | Ultomiris |
| Cormedix INC. | $37.59 | 2025 | Defencath |
| Arbor Pharmaceuticals, INC. | $30.87 | 2020-2021 | |
| Hikma Pharmaceuticals USA | $30.45 | 2020-2023 | Mitigare |
| Opko Pharmaceuticals, LLC | $29.04 | 2019 | |
| Lundbeck LLC | $20.21 | 2021 | |
| Scpharmaceuticals INC. | $17.44 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Lambert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.